search
Back to results

Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer

Primary Purpose

Lung Cancer

Status
Completed
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
carboplatin
cisplatin
etoposide phosphate
pravastatin sodium
Sponsored by
University College, London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Cancer focused on measuring extensive stage small cell lung cancer, limited stage small cell lung cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed small cell lung cancer

    • Limited stage or extensive stage disease
  • No mixed cell histology
  • No symptomatic brain metastases that require immediate radiotherapy

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-3
  • Life expectancy > 8 weeks
  • Platelet count > 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL
  • Absolute neutrophil count > 1,500/mm^3
  • Glomerular filtration rate ≥ 50 mL/min
  • Creatine kinase ≤ 5 times upper limit of normal (ULN)
  • Liver function tests (ALP, ALT/AST, and bilirubin) < 3 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for at least 1 year after completion of chemotherapy/radiotherapy and for an additional 28 days after completion of pravastatin sodium
  • Able to tolerate chemotherapy
  • No evidence of significant medical condition or laboratory finding that, in the opinion of the investigator, would preclude study participation
  • No family history of hypercholesterolemia
  • No history of malignant tumor unless the patient has been without evidence of disease for ≥ 3 years or tumor was a nonmelanoma skin tumor or early cervical cancer

PRIOR CONCURRENT THERAPY:

  • More than 12 months since prior statin
  • More than 4 weeks since prior fibrates (e.g., bezofibrate, gemfibrozil, or fenofibrate)
  • No prior chemotherapy for this cancer
  • No prior radiotherapy for this cancer unless to distant metastases (i.e., not within the thorax or thoracic/cervical spine area)
  • No concurrent cyclosporine
  • Concurrent radiotherapy allowed

Sites / Locations

  • William Harvey Hospital
  • Stoke Mandeville Hospital
  • North Devon District Hospital
  • Royal United Hospital
  • City Hospital - Birmingham
  • Sandwell General Hospital
  • Good Hope Hospital
  • Birmingham Heartlands Hospital
  • Royal Bournemouth Hospital
  • Bradford Royal Infirmary
  • Sussex Cancer Centre at Royal Sussex County Hospital
  • Queen's Hospital
  • Addenbrooke's Hospital
  • Kent and Canterbury Hospital
  • Broomfield Hospital
  • Gloucestershire Oncology Centre at Cheltenham General Hospital
  • Essex County Hospital
  • Queen Alexandra Hospital
  • Darent Valley Hospital
  • Royal Derby Hospital
  • Dorset County Hospital
  • University Hospital of North Durham
  • Princess Alexandra Hospital
  • Royal Devon and Exeter Hospital
  • Gloucestershire Royal Hospital
  • Diana Princess of Wales Hospital
  • St. Luke's Cancer Centre at Royal Surrey County Hospital
  • Harrogate District Hospital
  • Hereford Hospitals
  • Wycombe General Hospital
  • Huddersfield Royal Infirmary
  • Castle Hill Hospital
  • Ipswich Hospital
  • Airedale General Hospital
  • Queen Elizabeth Hospital
  • Cancer Research UK Clinical Centre at St. James's University Hospital
  • Leicester Royal Infirmary
  • University College Hospital
  • Guy's Hospital
  • Queen Elizabeth Hospital - Woolwich
  • St. George's Hospital
  • Charing Cross Hospital
  • Luton and Dunstable Hospital
  • Maidstone Hospital
  • Christie Hospital
  • Wythenshawe Hospital
  • Queen Elizabeth The Queen Mother Hospital
  • James Cook University Hospital
  • Milton Keynes General Hospital
  • Freeman Hospital
  • St. Mary's Hospital
  • Friarage Hospital
  • Mount Vernon Cancer Centre at Mount Vernon Hospital
  • King's Mills Hospital
  • Northampton General Hospital
  • Nottingham City Hospital
  • Princess Royal University Hospital
  • Peterborough Hospitals Trust
  • Derriford Hospital
  • Dorset Cancer Centre
  • Berkshire Cancer Centre at Royal Berkshire Hospital
  • Salisbury District Hospital
  • Scarborough General Hospital
  • Scunthorpe General Hospital
  • Royal Shrewsbury Hospital
  • Wexham Park Hospital
  • South Tyneside District Hospital
  • Southampton General Hospital
  • Lister Hospital
  • Torbay Hospital
  • Walsall Manor Hospital
  • Weston General Hospital
  • New Cross Hospital
  • Worcestershire Royal Hospital
  • Worthing Hospital
  • Yeovil District Hospital
  • Cancer Care Centre at York Hospital
  • Aberdeen Royal Infirmary
  • Falkirk and District Royal Infirmary
  • Velindre Cancer Center at Velindre Hospital
  • Llandough Hospital
  • Nevill Hall Hospital
  • Withybush General Hospital
  • Royal Gwent Hospital
  • Glan Clwyd Hospital
  • Singleton Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Carboplatin/cisplatin and Etoposide with Pravastatin

Carboplatin/cisplatin and Etoposide with Placebo

Arm Description

Outcomes

Primary Outcome Measures

Survival

Secondary Outcome Measures

Progression-free survival
Local progression-free survival (local control)
Response rate as measured by RECIST criteria after course 3
Toxicity as measured by CTCAE version 3.0

Full Information

First Posted
February 8, 2007
Last Updated
December 1, 2014
Sponsor
University College, London
search

1. Study Identification

Unique Protocol Identification Number
NCT00433498
Brief Title
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
Official Title
A Multicentre Phase III Randomized Double Blind Placebo Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Patients With Small Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
November 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University College, London

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
RATIONALE: Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pravastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by making tumor cells more sensitive to chemotherapy. It is not yet known whether etoposide and cisplatin or carboplatin are more effective with or without pravastatin in treating small cell lung cancer. PURPOSE: This randomized phase III trial is studying etoposide and cisplatin or carboplatin to see how well they work when given as first-line chemotherapy together with pravastatin compared with first-line chemotherapy and a placebo in treating patients with small cell lung cancer.
Detailed Description
OBJECTIVES: Primary Compare the survival of patients with small cell lung cancer treated with etoposide phosphate in combination with cisplatin or carboplatin as first-line chemotherapy with vs without pravastatin. Secondary Compare the progression-free survival of patients treated with these regimens. Compare the local progression-free survival (local control) of these patients. Compare the response rate in these patients. Compare the toxicity of these regimens in these patients. OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to disease stage (limited stage vs extensive stage), ECOG performance status (0 or 1 vs 2 or 3), and participating site. Patients are randomized to 1 of 2 treatment arms. All patients receive chemotherapy comprising cisplatin IV or carboplatin IV on day 1 and etoposide phosphate IV on days 1-3 or orally twice daily on days 2 and 3. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Arm I: Patients receive oral pravastatin daily beginning on day 1 of chemotherapy and continuing for up to 24 months. Arm II: Patients receive oral placebo daily beginning on day 1 of chemotherapy and continuing for up to 24 months. Some patients may undergo blood and urine sample collection at baseline and periodically during and after study treatment. Samples are examined by genetic analysis, metabonomics and proteomics (to detect expression of RAS proteins, phospho-Erk, and other signals downstream of RAS), and cholesterol measurements. After completion of study treatment, patients are followed every 2 months for 1 year and every 3 months thereafter. Peer Reviewed and Funded or Endorsed by Cancer Research UK. PROJECTED ACCRUAL: A total of 842 patients will be accrued for this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer
Keywords
extensive stage small cell lung cancer, limited stage small cell lung cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
846 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Carboplatin/cisplatin and Etoposide with Pravastatin
Arm Type
Experimental
Arm Title
Carboplatin/cisplatin and Etoposide with Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
carboplatin
Intervention Description
Should be given according to local practice but suggested doses and schedules are provided in the protocol.
Intervention Type
Drug
Intervention Name(s)
cisplatin
Intervention Description
Should be given according to local practice but suggested doses and schedules are provided in the protocol.
Intervention Type
Drug
Intervention Name(s)
etoposide phosphate
Intervention Description
Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
Intervention Type
Drug
Intervention Name(s)
pravastatin sodium
Intervention Description
40mg daily oral tablet taken for a maximum of 2 years
Primary Outcome Measure Information:
Title
Survival
Time Frame
Reported at death.
Secondary Outcome Measure Information:
Title
Progression-free survival
Time Frame
Time until the date of disease progression
Title
Local progression-free survival (local control)
Time Frame
Time until the date of disease progression
Title
Response rate as measured by RECIST criteria after course 3
Time Frame
Post chemo cycle 3
Title
Toxicity as measured by CTCAE version 3.0
Time Frame
At every clinic visit or if serious, an SAE form shoudl be submitted

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed small cell lung cancer Limited stage or extensive stage disease No mixed cell histology No symptomatic brain metastases that require immediate radiotherapy PATIENT CHARACTERISTICS: ECOG performance status 0-3 Life expectancy > 8 weeks Platelet count > 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count > 1,500/mm^3 Glomerular filtration rate ≥ 50 mL/min Creatine kinase ≤ 5 times upper limit of normal (ULN) Liver function tests (ALP, ALT/AST, and bilirubin) < 3 times ULN Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for at least 1 year after completion of chemotherapy/radiotherapy and for an additional 28 days after completion of pravastatin sodium Able to tolerate chemotherapy No evidence of significant medical condition or laboratory finding that, in the opinion of the investigator, would preclude study participation No family history of hypercholesterolemia No history of malignant tumor unless the patient has been without evidence of disease for ≥ 3 years or tumor was a nonmelanoma skin tumor or early cervical cancer PRIOR CONCURRENT THERAPY: More than 12 months since prior statin More than 4 weeks since prior fibrates (e.g., bezofibrate, gemfibrozil, or fenofibrate) No prior chemotherapy for this cancer No prior radiotherapy for this cancer unless to distant metastases (i.e., not within the thorax or thoracic/cervical spine area) No concurrent cyclosporine Concurrent radiotherapy allowed
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael J. Seckl, MD, PhD
Organizational Affiliation
Charing Cross Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
William Harvey Hospital
City
Ashford-Kent
State/Province
England
ZIP/Postal Code
TN24 0LZ
Country
United Kingdom
Facility Name
Stoke Mandeville Hospital
City
Aylesbury-Buckinghamshire
State/Province
England
ZIP/Postal Code
HP21 8AL
Country
United Kingdom
Facility Name
North Devon District Hospital
City
Barnstaple
State/Province
England
ZIP/Postal Code
EX31 4JB
Country
United Kingdom
Facility Name
Royal United Hospital
City
Bath
State/Province
England
ZIP/Postal Code
BA1 3NG
Country
United Kingdom
Facility Name
City Hospital - Birmingham
City
Birmingham
State/Province
England
ZIP/Postal Code
B18 7QH
Country
United Kingdom
Facility Name
Sandwell General Hospital
City
Birmingham
State/Province
England
ZIP/Postal Code
B71 4HJ
Country
United Kingdom
Facility Name
Good Hope Hospital
City
Birmingham
State/Province
England
ZIP/Postal Code
B75 7RR
Country
United Kingdom
Facility Name
Birmingham Heartlands Hospital
City
Birmingham
State/Province
England
ZIP/Postal Code
B9 5SS
Country
United Kingdom
Facility Name
Royal Bournemouth Hospital
City
Bournemouth
State/Province
England
ZIP/Postal Code
BH7 7DW
Country
United Kingdom
Facility Name
Bradford Royal Infirmary
City
Bradford
State/Province
England
ZIP/Postal Code
BD9 6RJ
Country
United Kingdom
Facility Name
Sussex Cancer Centre at Royal Sussex County Hospital
City
Brighton
State/Province
England
ZIP/Postal Code
BN2 5BE
Country
United Kingdom
Facility Name
Queen's Hospital
City
Burton-upon-Trent
State/Province
England
ZIP/Postal Code
DE13 0RB
Country
United Kingdom
Facility Name
Addenbrooke's Hospital
City
Cambridge
State/Province
England
ZIP/Postal Code
CB2 2QQ
Country
United Kingdom
Facility Name
Kent and Canterbury Hospital
City
Canterbury
State/Province
England
ZIP/Postal Code
CT1 3NG
Country
United Kingdom
Facility Name
Broomfield Hospital
City
Chelmsford
State/Province
England
ZIP/Postal Code
CM1 7ET
Country
United Kingdom
Facility Name
Gloucestershire Oncology Centre at Cheltenham General Hospital
City
Cheltenham
State/Province
England
ZIP/Postal Code
GL53 7AN
Country
United Kingdom
Facility Name
Essex County Hospital
City
Colchester
State/Province
England
ZIP/Postal Code
C03 3NB
Country
United Kingdom
Facility Name
Queen Alexandra Hospital
City
Cosham
State/Province
England
ZIP/Postal Code
PO6 3LY
Country
United Kingdom
Facility Name
Darent Valley Hospital
City
Dartford Kent
State/Province
England
ZIP/Postal Code
DA2 8DA
Country
United Kingdom
Facility Name
Royal Derby Hospital
City
Derby
State/Province
England
ZIP/Postal Code
DE22 3NE
Country
United Kingdom
Facility Name
Dorset County Hospital
City
Dorchester
State/Province
England
ZIP/Postal Code
DT1 2JY
Country
United Kingdom
Facility Name
University Hospital of North Durham
City
Durham
State/Province
England
ZIP/Postal Code
DH1 5TW
Country
United Kingdom
Facility Name
Princess Alexandra Hospital
City
Essex
State/Province
England
ZIP/Postal Code
CM20 1QX
Country
United Kingdom
Facility Name
Royal Devon and Exeter Hospital
City
Exeter
State/Province
England
ZIP/Postal Code
EX2 5DW
Country
United Kingdom
Facility Name
Gloucestershire Royal Hospital
City
Gloucester
State/Province
England
ZIP/Postal Code
GL1 3NN
Country
United Kingdom
Facility Name
Diana Princess of Wales Hospital
City
Grimsby
State/Province
England
ZIP/Postal Code
DN33 2BA
Country
United Kingdom
Facility Name
St. Luke's Cancer Centre at Royal Surrey County Hospital
City
Guildford
State/Province
England
ZIP/Postal Code
GU2 7XX
Country
United Kingdom
Facility Name
Harrogate District Hospital
City
Harrogate
State/Province
England
ZIP/Postal Code
HG2 7SX
Country
United Kingdom
Facility Name
Hereford Hospitals
City
Hereford
State/Province
England
ZIP/Postal Code
HR1 2ER
Country
United Kingdom
Facility Name
Wycombe General Hospital
City
High Wycombe
State/Province
England
Country
United Kingdom
Facility Name
Huddersfield Royal Infirmary
City
Huddersfield, West Yorks
State/Province
England
ZIP/Postal Code
HD3 3EA
Country
United Kingdom
Facility Name
Castle Hill Hospital
City
Hull
State/Province
England
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Facility Name
Ipswich Hospital
City
Ipswich
State/Province
England
ZIP/Postal Code
IP4 5PD
Country
United Kingdom
Facility Name
Airedale General Hospital
City
Keighley
State/Province
England
ZIP/Postal Code
BD20 6TD
Country
United Kingdom
Facility Name
Queen Elizabeth Hospital
City
King's Lynn
State/Province
England
ZIP/Postal Code
PE30 4ET
Country
United Kingdom
Facility Name
Cancer Research UK Clinical Centre at St. James's University Hospital
City
Leeds
State/Province
England
ZIP/Postal Code
LS16 6QB
Country
United Kingdom
Facility Name
Leicester Royal Infirmary
City
Leicester
State/Province
England
ZIP/Postal Code
LE1 5WW
Country
United Kingdom
Facility Name
University College Hospital
City
London
State/Province
England
ZIP/Postal Code
NW1 2BU
Country
United Kingdom
Facility Name
Guy's Hospital
City
London
State/Province
England
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
Queen Elizabeth Hospital - Woolwich
City
London
State/Province
England
ZIP/Postal Code
SE18 4QH
Country
United Kingdom
Facility Name
St. George's Hospital
City
London
State/Province
England
ZIP/Postal Code
SW17 0QT
Country
United Kingdom
Facility Name
Charing Cross Hospital
City
London
State/Province
England
ZIP/Postal Code
W6 8RF
Country
United Kingdom
Facility Name
Luton and Dunstable Hospital
City
Luton
State/Province
England
ZIP/Postal Code
LU4 0DZ
Country
United Kingdom
Facility Name
Maidstone Hospital
City
Maidstone
State/Province
England
ZIP/Postal Code
ME16 9QQ
Country
United Kingdom
Facility Name
Christie Hospital
City
Manchester
State/Province
England
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Facility Name
Wythenshawe Hospital
City
Manchester
State/Province
England
ZIP/Postal Code
M23 9LJ
Country
United Kingdom
Facility Name
Queen Elizabeth The Queen Mother Hospital
City
Margate
State/Province
England
ZIP/Postal Code
CT9 4AN
Country
United Kingdom
Facility Name
James Cook University Hospital
City
Middlesbrough
State/Province
England
ZIP/Postal Code
TS4 3BW
Country
United Kingdom
Facility Name
Milton Keynes General Hospital
City
Milton Keynes
State/Province
England
ZIP/Postal Code
MK6 5LD
Country
United Kingdom
Facility Name
Freeman Hospital
City
Newcastle-Upon-Tyne
State/Province
England
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Facility Name
St. Mary's Hospital
City
Newport
State/Province
England
ZIP/Postal Code
PO30 5TG
Country
United Kingdom
Facility Name
Friarage Hospital
City
North Yorkshire
State/Province
England
ZIP/Postal Code
DL6 1JG
Country
United Kingdom
Facility Name
Mount Vernon Cancer Centre at Mount Vernon Hospital
City
Northwood
State/Province
England
ZIP/Postal Code
HA6 2RN
Country
United Kingdom
Facility Name
King's Mills Hospital
City
Nottinghamshire
State/Province
England
ZIP/Postal Code
NG17 4JL
Country
United Kingdom
Facility Name
Northampton General Hospital
City
Nottingham
State/Province
England
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Facility Name
Nottingham City Hospital
City
Nottingham
State/Province
England
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Facility Name
Princess Royal University Hospital
City
Orpington, Kent
State/Province
England
ZIP/Postal Code
BR6 8ND
Country
United Kingdom
Facility Name
Peterborough Hospitals Trust
City
Peterborough
State/Province
England
ZIP/Postal Code
PE3 6DA
Country
United Kingdom
Facility Name
Derriford Hospital
City
Plymouth
State/Province
England
ZIP/Postal Code
PL6 8DH
Country
United Kingdom
Facility Name
Dorset Cancer Centre
City
Poole Dorset
State/Province
England
ZIP/Postal Code
BH15 2JB
Country
United Kingdom
Facility Name
Berkshire Cancer Centre at Royal Berkshire Hospital
City
Reading
State/Province
England
ZIP/Postal Code
RG1 5AN
Country
United Kingdom
Facility Name
Salisbury District Hospital
City
Salisbury
State/Province
England
ZIP/Postal Code
SP2 8BJ
Country
United Kingdom
Facility Name
Scarborough General Hospital
City
Scarborough
State/Province
England
ZIP/Postal Code
YO12 6QL
Country
United Kingdom
Facility Name
Scunthorpe General Hospital
City
Scunthorpe
State/Province
England
ZIP/Postal Code
DN15 7BH
Country
United Kingdom
Facility Name
Royal Shrewsbury Hospital
City
Shrewsbury
State/Province
England
ZIP/Postal Code
SY3 8XQ
Country
United Kingdom
Facility Name
Wexham Park Hospital
City
Slough, Berkshire
State/Province
England
ZIP/Postal Code
SL2 4HL
Country
United Kingdom
Facility Name
South Tyneside District Hospital
City
South Shields
State/Province
England
ZIP/Postal Code
NE34 0PL
Country
United Kingdom
Facility Name
Southampton General Hospital
City
Southampton
State/Province
England
ZIP/Postal Code
SO16 6YD
Country
United Kingdom
Facility Name
Lister Hospital
City
Stevenage
State/Province
England
ZIP/Postal Code
SG1 4AB
Country
United Kingdom
Facility Name
Torbay Hospital
City
Torquay
State/Province
England
ZIP/Postal Code
TQ2 7AA
Country
United Kingdom
Facility Name
Walsall Manor Hospital
City
Walsall
State/Province
England
ZIP/Postal Code
WS2 9PS
Country
United Kingdom
Facility Name
Weston General Hospital
City
Weston-super-Mare
State/Province
England
ZIP/Postal Code
BS23 4TQ
Country
United Kingdom
Facility Name
New Cross Hospital
City
Wolverhampton
State/Province
England
ZIP/Postal Code
WV10 0QP
Country
United Kingdom
Facility Name
Worcestershire Royal Hospital
City
Worcester
State/Province
England
ZIP/Postal Code
WR5 1AN
Country
United Kingdom
Facility Name
Worthing Hospital
City
Worthing
State/Province
England
ZIP/Postal Code
BN11 2DH
Country
United Kingdom
Facility Name
Yeovil District Hospital
City
Yeovil
State/Province
England
ZIP/Postal Code
BA21 4AT
Country
United Kingdom
Facility Name
Cancer Care Centre at York Hospital
City
York
State/Province
England
ZIP/Postal Code
Y031 8HE
Country
United Kingdom
Facility Name
Aberdeen Royal Infirmary
City
Aberdeen
State/Province
Scotland
ZIP/Postal Code
AB25 2ZN
Country
United Kingdom
Facility Name
Falkirk and District Royal Infirmary
City
Falkirk
State/Province
Scotland
ZIP/Postal Code
FK1 5QE
Country
United Kingdom
Facility Name
Velindre Cancer Center at Velindre Hospital
City
Cardiff
State/Province
Wales
ZIP/Postal Code
CF14 2TL
Country
United Kingdom
Facility Name
Llandough Hospital
City
Cardiff
State/Province
Wales
ZIP/Postal Code
CF64 2XX
Country
United Kingdom
Facility Name
Nevill Hall Hospital
City
Gwent
State/Province
Wales
Country
United Kingdom
Facility Name
Withybush General Hospital
City
Haverfordwest
State/Province
Wales
ZIP/Postal Code
SA61 2PZ
Country
United Kingdom
Facility Name
Royal Gwent Hospital
City
Newport Gwent
State/Province
Wales
ZIP/Postal Code
NP9 2UB
Country
United Kingdom
Facility Name
Glan Clwyd Hospital
City
Rhyl, Denbighshire
State/Province
Wales
ZIP/Postal Code
LL 18 5UJ
Country
United Kingdom
Facility Name
Singleton Hospital
City
Swansea
State/Province
Wales
ZIP/Postal Code
SA2 8QA
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer

We'll reach out to this number within 24 hrs